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ABSTRACT
Objective: Hepatitis B virus ( HBV ) and hepatitis 
C virus ( HCV ) infections are important health 
problems throughout the world. These virus 
infections can cause chronic hepatitis, cirrhosis 
or hepatocellular carcinoma. The association of 
diabetes mellitus with liver disease was 
recognized many years ago and it has been 
documented in numerous studies. This 
association might be related to diabetes mellitus 
causing chronic liver disease or vice versa. It was 
reported that diabetes mellitus seems to be more 
frequent in chronic hepatitis C cases and patients 
who have type II diabetes mellitus have higher 
antiHCV seropositivity than normal. For this 
reason, frequency of HBsAg, antiHBs, antiHCV 
and its relation to the duration of diabetes, age of 
patients, and type of antidiabetics used was 
evaluated among our hospital diabetic outpatient 
clinic patients in the present study.
Methods: Seventy-four type I and II diabetic 
patients followed by Haydarpaşa Numune 
Education and Research Hospital Diabetic's
outpatient clinic between October 1999 and 
March 2000, participated in this study. The 3rd 
generation ELISA method was used for hepatitis 
markers detection with the " The Organon 
Technica " kits.
Results: According to our study results, the 
frequency of HBsAg, antiHBs, antiHCV was 
found to be 4 %, 29 %, 4 % respectively among 
our study group. It was seen that antiHCV 
seropositivity in diabetic patients is higher than 
normal population. There is no statistical 
relationship between the hepatitis B and C 
markers positivity and age, duration of diabetes 
mellitus and type of antidiabetics used.
Conclusion: As a result HBV incidence is similar 
to the normal population whereas HCV infection 
incidence is higher among diabetics than in the 
normal population. However to clarify the 
incidence of HCV infection among diabetic 
patients, we need further confirmative studies.
K e y  W o rd s : HBV, HCV, Diabetes mellitus.
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INTRO DUC TIO N
Viral hepatitis is one of the most common 
infections. The known causative agents are 
hepatitis A virus (HAV), hepatitis B virus (HBV), 
hepatitis C virus (HCV), hepatitis delta virus 
(HDV), hepatitis E virus (HEV) and newer 
hepatitis virus such as hepatitis F virus (HFV), 
hepatitis G virus (HGV) and transfusion - 
transmissible virus (TTV). The viral hepatitis can 
be acute or chronic. Chronic hepatitis is mostly 
caused by HBV, HCV, HDV. Chronic hepatitis is 
a well known risk factor for cirrhosis and 
hepatocellular carcinoma (1-4).
Hepatitis B virus infection is one of the most 
important health problems in the world. It was 
reported that more than two billion people are 
confronted with HBV. Hepatitis C virus infection 
is also an important health problem throughout 
the world as HBV infection. These virus 
infections can cause chronic hepatitis, cirrhosis, 
and hepatocellular carcinoma. The host immunity 
is very important in progressive cases ( 3,4 ).
Diabetes mellitus is one of the most common 
endocrine diseases. The diabetes mellitus 
incidence is 1-2 % according to the fasting 
hyperglycemia. The disease is characterized by 
metabolic abnormalities and long term 
complications. The effect of diabetes mellitus on 
the immune system, and the association of 
diabetes mellitus with chronic liver disease is 
shown in many studies (5,6). The diabetes 
mellitus incidence is high especially in patients 
with chronic HCV infection and anti HCV 
positivity is reported more frequently in type II 
diabetic patients than in the normal population 
(7). AntiHBs positivity was found to be high in 
some previous studies, propably due to 
inappropriate use of the insulin syringe. In recent 
years this incidence decreased with improved 
hygienic conditions ( 8-10 ). In this study the 
frequency of HBsAg, antiHBs, antiHCV and its 
relation to the duration of diabetes, and type of 
antidiabetics used was evaluated among our 
hospital diabetic outpatient clinic patients.
M ATERIAL A N D  M ETHO D
Seventy-four type I and II diabetic patients were 
followed by Haydarpaşa Numune Education and
Research Hospital Diabetic's outpatient clinic 
between October 1999 and March 2000, 
participated in this study. All patients were 
questioned about the antidiabetic medications 
(oral, insulin) they used, how long they had 
known that they were diabetic, how long they had 
been using antidiabetics, whether they had had 
any operation previously, whether they had had 
any blood or blood products transfusions, 
whether they had had hepatitis before. We 
collected the serum of patients to assess 
antiHCV, HBsAg, antiHBs, antiHBc total status 
with biochemical parameters. The 3rd generation 
ELISA method was used for hepatitis markers 
detection with the "The Organon Technica" kits. 
The statistical analysis was done via Student's 
t test, Fisher's exact test and Pearson's 
correlation analysis test. One sample Student's t 
test was used for comparing HBsAg and 
antiHCV positivity between diabetics and Turkey 
average. Fisher's exact test was used to 
coanalyse antiHBc status and type of used 
antidiabetic. The relationship between antiHBc 
status and the duration of diabetes mellitus was 
analysed by Pearson’s correlation analysis test. 
The relationship between antiHBc status and age 
in diabetics was analysed by Pearson's 
correlation analysis test.
RESULTS
Forty nine of 74 diabetic patients were female 
and 25 were male. Twenty three of the patients 
were using insulin, 48 of 74 patients were taking 
oral antidiabetics. Three patients had had on 
antidiabetic regime. The mean age of the 
diabetics was 54.98.
Forty two of 74 patients ( 56.7 % ) had negative 
hepatitis markers against HBV. Two patients (2.7 
%) were only antiHBs positive, 5 patients ( 6.8 %) 
were only antiHBcIgG positive, 22 patients (29.8 
%) were antiHBs and antiHBcIgG positive, 3 
patients ( 4 % ) were HBsAg and antiHBcIgG 
positive, 3 patients ( 4 % ) were antiHCV positive 
and one of them was HBsAg and antiHBcIgG 
positive ( Table I ). One patient had both chronic 
HBV and HCV infection.The other had antiHCV 
positive. According to our study HBs Ag positivity 
is found in the normal range due to Turkey 
average values. AntiHCV positivity is over the 
Turkey average (Table II, p<0.05).
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T a b le  I: The distribution of hepatitis markers among 74 
diabetic patients
n (%)
HBsAg and antiHBcIgG positivity (n) 3 4.0
antiHBs and antiHBcIgG positivity (n) 22 29.7
antiHBcIgG positivity (n) 5 6.8
antiHBs positivity (n) 2 2.7*
antiHCV positivity (n) 3 4.0
* Vaccinated
T a b le  II: The comparison of HBsAg and antiHCV positivity 
between diabetic patients and Turkey average
antiHCV (+) HBsAg (+)
Diabetic patients (%) 4% 4%
Turkey average* 0.6% (0.2-1%) 5% (4-11%)
t= 41.991 (one sample Student’s t test), p = 0.0006 (p<0.05)
*(1,19)
We investigated whether there is any relation 
between oral antidiabetics or insulin use and the 
HBsAg, antiHBcIgG, antiHBs, antiHCV positivity. 
Our study results show that there is no relation 
between hepatitis B virus frequency and the type 
of antidiabetics used (Table III, p>0.05). All three 
antiHCV positive patients were using insulin.
We also tried to assess the relation between the 
duration of diabetes mellitus or age and HBsAg, 
antiHBcIgG, antiHBs, antiHCV positivity. 
According to our study results there is no relation 
between hepatitis B frequency and the duration 
of diabetes mellitus or age (Table IV, Table V, 
p>0.05 ). The duration of diabetes mellitus in anti 
HCV positive patients was 15 years, 1.5 years, 6 
years. AntiHCV positive patients were 49,58,22 
years old respectively.
T a b le  III: The distribution of hepatitis B markers among 
insulin, oral antidiabetic user and antidiabetic diet 
taking patients.
—  
HBsAg (+) and 
antiHBcIgG (+)
antiHBs (+) and 
antiHBcIgG (+)
antiHBcIgG (+)
—  
Total (n)
Insulin 1 7 0 8
Oral antidiabetic 2 12 5 19
Antidiabetic diet 0 3 0 3
Total (n) 3
___________
22 5 30
p= 0.7967 (Fisher’s exact test), Odds ratio: 0,8140
T a b le  IV : The d is tribu tion  of antiH BcIgG  positiv ity  and 
negativity with the duration of diabetes mellitus
Duration of 
diabetes mellitus
antiHBcIgG (+) antiHBcIgG (-) Total (n)
0-5 year 6 16 22
6-10 year 11 12 23
11-15 year 3 7 10
16-20 year 4 4 8
21 and upper year 6 5 11
Total (n) 30 44 74
r= 0.4960 (Pearson's correlation analysis test), 
The two-tailed p value is 0.3954.
T a b le  V : The d is tribu tion  of antiHBcIgG  positiv ity  and 
negativity with age of diabetics
Period antiHBcIgG (+) antiHBcIgG (-) Total (n)
15-24 0 1 1
24-34 0 1 1
35-44 2 2 4
45-54 8 18 26
55-64 9 17 26
65 and upper 11 5 16
Total (n) 30 44 74
t = 0.4797 (Pearson's correlation analysis test), 
The two-tailed p value is 0.1272.
DISCUSSION
Diabetes mellitus and chronic liver disease 
association have been implicated for many 
years. Initially diabetes mellitus can cause direct 
liver damage. Nuclear and cytoplasmic glycogen 
accumulation, lipid deposition and perisinouidal 
fibrosis are commonly seen in diabetics. And 
there are some reports that cirrhosis is one of the 
infrequent complications of diabetes mellitus. In 
recent years, it was shown that diabetes mellitus 
can cause nonalcoholic hepatosteatosis or 
cirrhosis. The prevalence of diabetes mellitus 
and cirrhosis has wide variations. Similarly 
chronic liver disease could also cause diabetes 
mellitus. More than 70 % of cirrhotics have 
abnormal oral glucose tolerance test ( OGTT ). 
There may be hyperinsulinism and insulin 
resistance ( 5,6 ).
Hepatitis B virus ( HBV ) and hepatitis C virus 
(HCV) infections are important health problems
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throughout the world. These virus infections can 
cause chronic hepatitis, cirrhosis or 
hepatocellular carcinoma. The diabetes mellitus 
incidence is high especially in patients with 
chronic HCV infection and antiHCV positivity is 
reported more frequently in type II diabetics than 
normal population. There are many studies 
related to incidence of HBV and HCV infection in 
diabetics that support increased frequency of 
HCV infection. But these studies are not 
systematically designed. The HBV or HCV 
infection incidence among diabetics has been 
found more frequently than normal population in 
various studies. This increased frequency 
might be associated with frequent parenteral 
applications or prolonged hospitalization in these 
patients. In recent years authors concluded that 
chronic HCV infection incidence was higher than 
HBV infection in diabetics. And they also had 
found that HCV incidence was higher than HBV 
infection in diabetics. And they also had found 
that HCV incidence was higher in diabetics than 
in the controls (4,7,11-15). Özyılkan et al (16) 
found 8% antiHCV positivity which was higher 
than in the normal population. Frasser et al (15) 
found that antiHCV positivity was higher in 
diabetics than in the normal population and that 
HBV incidence was close to that in the normal 
population. Balık et al (17) also found 6% 
antiHCV positivity and 5% HBsAg positivity. 
Another study from Bederida and et al (18) 
among 2465 diabetics concluded that HBsAg 
positivity was less than in the controls (3.5% 
and 6.9% respectively). They found high 
antiHCV incidence among diabetic patients that 
may be associated with T cell response 
resistance. According to our study results the 
HBsAg positivity is 4 % (p>0.05), antiHBs 
positivity is 29% (p>0.05), antiHCV positivity is 
4% (p>0.05). The only antiHBcIgG positivity is 
6.8% and the liver function tests of these patients 
are normal, this condition can be probably due to 
deficient immunity. We concluded that HBV 
frequency was not more than in the normal 
population among our outpatient diabetic clinics 
patients, and HCV positivity with 4 % was clearly 
more than in the normal population.This result 
correlates with other studies.
It was documented with various investigations 
whether there was any relationship between oral 
antidiabetics or insulin use and the HBsAg, 
antiHBcIgG, antiHBs, antiHCV positivity. The
HBsAg positivity was 6.9% among insulin users 
whereas it was 8.6% in oral antidiabetic using 
patients in Colloredo-Mels et al's study ( 19 ). 
According to this study the chronic liver disease 
incidence was not higher in diabetics than in the 
normal population. They concluded that insulin 
treatment was not a risk factor for HBV infection. 
And in another study carried out among 210 
insulin user diabetic patients by Olio et al ( 20 ), 
the positivity of HBsAg was 9 % in diabetics 
where as it was 2.9 % in nondiabetics. Our study 
results also support the recently documented 
studies that there is no relation between the type 
of antidiabetics used and HBV infection. 
According to Olio et al ( 20 ), the newer diabetics 
have lesser HBV positivity than older diabetic 
patients. According to our study results there is 
not any association between the period of 
antidiabetic use and HBV, HCV infection 
incidence. Colleredo-Mels et al ( 19 ) concluded 
that increased age and HCV infection frequency 
was higher than HBV infection and they also 
concluded that age was an independent factor. 
According to our study results there is no relation 
between age and HBV infection. As a result HBV 
incidence is similar with the normal population 
where as HCV infection is higher among 
diabetics than in the normal population. 
However, to clarify the incidence of HCV infection 
among diabetic patient, we need further studies.
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